ProteoNic 2G UNic® Technology Licensed by Ginkgo Bioworks for BARDA-Supported Consortium Advancing Monoclonal Antibody Manufacturing for Anti-Filovirus Therapies

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo ...
Nasdaq

ProteoNic Announces Licensing of its 2G UNic™ Technology Platform for Production of Biologics to Gilead Sciences

LEIDEN, Netherlands, Nov. 5, 2020 /PRNewswire/ -- ProteoNic, a leading provider of technology and services for efficient production of biologics, today announced it has licensed its premium 2G UNic™ ...